Original Research

Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review

SeyedAhmad SeyedAlinaghi1, Amirali Karimi2, Zahra Pashaei1, Arian Aفزیان2, Pegah Mirzapour1, Kobra Ghorbanzadeh3, Afshaneh Ghasemzadeh4, Mohsen Dashti1, Newsha Nazarian5, Farzin Vahedi2, Marcarious M. Tantuoyir6,7, Ahmadreza Shamsabadi2, Omid Dadras1,8, Esmaeil Mehræen1,9

1. Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
2. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
3. Department of Nursing, Khalkhal University of Medical Sciences; Khalkhal, Iran.
4. Department of Radiology, Tabriz University of Medical Sciences, Tabriz, Iran.
5. School of Medicine, Islamic Azad University, Tehran, Iran.
6. Biomedical Engineering Unit, University of Ghana Medical Center (UGMC), Accra, Ghana.
7. Department of Health Information Technology, Esfarayen Faculty of Medical Sciences, Esfarayen, Iran.
8. School of Public Health, Walailak University, Nakhon Si Thammarat, Thailand.
9. Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran.

Received: March 2022; Accepted: April 2022; Published online: 28 May 2022

Abstract: Introduction: Knowledge of vaccine-related adverse events is crucial as they are among the most important factors that cause hesitation in receiving vaccines. Therefore, we aimed to systematically review the adverse events related to the mRNA vaccines reported in the literature. Methods: A systematic literature search was carried out in the databases of Scopus, PubMed, Cochrane, and Web of Science. We selected original studies that explored the side effects of mRNA COVID-19 vaccines using a two-phase (title/abstract and full-text) screening process. Results: Cardiac complications were the most commonly reported severe adverse events. It appeared that systemic adverse reactions are more common after the second dose of vaccines. The number of adverse effects reported after the Pfizer vaccine was higher than other vaccines, mostly due to its earlier approval and more widespread use throughout the world. Cardiac adverse events had a higher prevalence but no significant association has been found between COVID-19 mRNA vaccines and cardiac adverse events except for myocarditis.

Conclusion: Vaccines play a crucial role in controlling the COVID-19 pandemic and decreasing mortalities and the results of the present review acknowledge the fact that the benefits outweigh the adverse events of these vaccines.

Keywords: Adverse effects; COVID-19 vaccines; 2019-nCoV Vaccine mRNA-1273; mRNA vaccines; BNT162 Vaccine

Cite this article as: SeyedAlinaghi S, Karimi A, Pashaei Z, Aفزیان A, Mirzapour P, Ghorbanzadeh K, Ghasemzadeh A, Dashti M, Nazarian N, Vahedi F, Tantuoyir MM, Shamsabadi A, Dadras O, Mehræen E. Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review. Arch Acad Emerg Med. 2022; 10(1); e41. https://doi.org/10.22037/aaem.v10i1.1597.

1. Introduction

The COVID-19 pandemic is a global health crisis that demands enormous measures in order to be controlled. Mass vaccination of the population is critical for containing it; thus, countries all over the world are attempting to vaccinate their people against this disease (1–4). Vaccines operate by stimulating the body’s natural immunological response. Immediately after the genetic sequence of the novel coronavirus
was uncovered, vaccine manufacturers all around the world jumped into action to develop a vaccine (5). Currently available SARS-CoV-2 vaccines are produced using one of the following technologies: mRNA-based vaccines, whole virus or inactivated virus vaccines, protein subunit vaccines, and viral vector-based vaccines (6).

Pfizer-BioNTech BNT162b2 and Moderna mRNA1273 are the first and only mRNA-based vaccines approved by the World Health Organization so far and have been used in several countries. These vaccines encode a stable full-length SARS-CoV-2 spike ectodomain, derived from the Wuhan-Hu-1 genetic sequence (7, 8). They are a novel-nucleic acid type of vaccine that employs genomic information such as messenger RNA (mRNA), a method that introduces a portion of the genetic code into human cells (9, 10). Furthermore, the high level of reactogenicity of the SARS-CoV-2 mRNA vaccines is one of their distinguishing features, provoking both local and systemic reactions observed by the majority of patients in Phase 1-3 trials. Additionally, the levels of systemic reactogenicity associated with SARS-CoV-2 mRNA vaccines have generated concerns about a more serious adverse event profile in patients with underlying immunological dysregulation as these patients, who often consume immunosuppressive and biologic medications for immune-mediated inflammatory illnesses such as inflammatory bowel disease (IBD), were mostly exempted from the vaccine trials. Activation of the innate immune system through pattern-recognition receptor ligation, followed by the production of inflammatory cytokines such as tumor necrosis factor, interleukin-6, and interleukin-1 is often responsible for the vaccine’s reactogenicity (11, 12).

Adverse drug reactions (ADRs) and medication-related incidents could be fatal, likewise, the side effect of vaccines could be catastrophic. If clinical trials are not powered enough to detect the very rare events, these rare but important adverse events may go undetected. Due to variances in age, race, and underlying conditions, the reported rates of adverse effects have been inconsistent across different studies. Even though their safety has been established, concerns of immune-mediated disease flare-ups or new-onset inflammatory diseases following their administration have recently emerged (13-16). The Vaccine Adverse Event Reporting System (VAERS), co-developed and maintained by the Centers for Disease Control and Prevention (CDC) and the United States Food and Drug Administration (FDA), serves as a national passive surveillance system for continuous monitoring of vaccine safety once it has been distributed in the market (17). The data from VAERS show that the most commonly reported side effects are injection site pain, fever, headache, neck pain, nausea, vomiting, drowsiness, diarrhea, dizziness, enlarged lymph nodes, decreased alcohol tolerance, dyspnea, cough, stuffy nose, fainting, thirst, excessive sweating, sore throat, loss of appetite, insomnia, irritability, stupor, photosensitivity, eye pain, numbness in the extremities, and malaise (18-20).

Vaccine safety is important to the success of any vaccination effort, particularly during a pandemic. Hence, with the increase in vaccination rates, it is crucial to monitor their adverse events post-vaccination. Raising awareness of associated adverse events (AEs) is crucial for reducing vaccine hesitancy as well as improving the safety of vaccines if necessary (21). Therefore, in this study, we aimed to systematically review the adverse events related to the mRNA vaccines reported in the literature. The findings could present and enhance scientific literacy across the many stakeholders and provide concise and evidence-based solutions to the COVID-19 vaccine safety concerns.

2. Methods

This review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic search of relevant records was carried out in the online databases using selected keywords on September 15th, 2021.

2.1. Data sources

We carried out a systematic search using the keywords and search queries in online databases including Scopus, PubMed, Cochrane, and Web of Science.

2.2. Search strategy

Search strategies were constructed by two authors of the research team. Search terms were connected in a highly-sensitive syntax via the Boolean operator OR. The search strategy that was used to retrieve the records in each online database is as follows:

\[
\text{(((([(COVID-19)[Title]] OR (SARS-CoV-2)[Title]))) OR (SARS-CoV2)[Title]))) OR (2019-nCoV)[Title]]) OR (Novel Coronavirus)[Title]]) AND ((([(Vaccine*)[Title]]) OR (Vaccination)[Title]]) OR (Vacinated)[Title]]) OR (Immunization)[Title]]) AND ((([(Safety)[Title]] OR (Side effect*)[Title]]) OR (Adverse event*[Title]))) OR (Adverse reaction*[Title])) OR
\]

2.3. Eligibility criteria

Original English articles that reported the adverse events of mRNA COVID-19 vaccine were included, applying the following exclusion criteria:

1) Abstracts/conference abstracts or unavailability of full texts
2) Ongoing clinical trials with unpublished results
3) Non-original studies, including review articles, meta-analyses, protocols, and editorials
4) Studies on other types of vaccines rather than mRNA vaccines, or those only reporting efficacy of mRNA vaccines without reporting their adverse events
5) Protocols of randomized clinical trials (RCTs) and other original studies

2.4. Selection of studies and Data Screening

The EndNote X9 software was used to organize the retrieved articles. Search results from different databases were combined in a single EndNote library and duplicates were removed. Two authors independently screened the retrieved articles in two steps. First, the title and abstract of the retrieved records were screened and the ineligible articles were removed. The full texts of the remaining articles were reviewed based on the inclusion and exclusion criteria and the eligible studies were included in the final qualitative analysis of the results.

2.5. Data Extraction

The following data were independently extracted by four researchers: first author, type of study, country of research, manufacturer of the mRNA vaccine, sample population, age, gender, severe adverse events, time from the injection to the appearance of adverse events, and local and systemic adverse events. These findings were organized into a table and were used for qualitative synthesis. Another author reviewed the extracted data and addressed any inconsistencies that existed between authors.

2.6. Quality assessment

The Newcastle-Ottawa scale (NOS) was used to assess the quality of included studies. This criteria yields a maximum score of nine for questions regarding selection, comparability, and exposure (22). Studies with poor quality assessment scores of four or less were excluded from this systematic review.

3. Results

Our search yielded a total of 1062 studies, and two more records were identified through manual searching. After removing the 547 duplicates, 515 records remained. A total of 171 records were excluded in the title/abstract screenings, and 346 full-text reports were assessed for eligibility (344 from database search, two via manual searching). Finally, 74 studies were found to be eligible for this systematic review (Figure 1).

The mean NOS quality assessment score of the studies was 6.5. No study had a score of four or less and therefore, no study was excluded from this systematic review due to low quality score. The purpose of this study was to review and describe the
findings of articles that reported safety and adverse events related to COVID-19 mRNA vaccines. We included articles that investigated the adverse effects of COVID-19 mRNA vaccines (Pfizer-BioNTech, Moderna, BNT, and BNT162b1) in the 1st, 2nd, and 3rd-phase RCTs, cross-sectional, and cohort studies.

3.1. Adverse reactions

In both Pfizer and Moderna vaccines mild to moderate local and systemic adverse reactions were reported. The findings have shown that the incidence of systemic adverse reactions could increase following the second dose. Also, the prevalence of systemic adverse reactions in younger adults (age group of 18-55) was higher in comparison with older adults. Injection site pain and muscle pain were the most common local adverse reactions reported in studies. Also, headache was the most prevalent systemic adverse reaction, followed by fatigue, myalgia, chills, and fever. Other local adverse reactions included tenderness, redness, urticaria, rash and swelling, neck pain, hand numbness, erythema, induration, itching, local loss of hair, and edema. Some other less common systemic adverse reactions were as follows: body aches, gastrointestinal symptoms, arthralgia, nausea, vomiting, diarrhea, dizziness, vertigo, weakness, and visual symptoms (Table 1). It should be noted that adverse reactions and severe adverse events could affect all healthy, pregnant, and immunocompromised vaccine recipients.

3.2. Severe adverse events (SAE)

In this review, severe adverse events were reported and classified into five categories including cardiac, allergic, neurologic adverse events, and adverse events that may occur in pregnant and immunocompromised patients who received COVID-19 mRNA vaccines. The time interval between inoculation and onset of severe adverse events varied from one hour to 84 days after the injection of the first or second dose. Severe adverse events are reported as follows:

-Cardiac

Most of the reported severe adverse events were related to cardiac events. A cross-sectional study among 700 participants who received Pfizer-BioNTech reported severe chest pain (0.4%) and acute hypertension (0.3%) after the first vaccine shot (6). A retrospective study among 113 allogeneic hematopoietic stem cell transplant recipients, who received Pfizer and Moderna vaccines, reported tachycardia and increased blood pressure (0.8%) (23). In a 3rd phase RCT among 14134 participants who received mRNA-1273 (Moderna), the authors reported one case of cardiopulmonary arrest (0.007%) (24). Another study on 884,828 participants who received Pfizer vaccine reported myocarditis (risk ratio, 3.24 and risk difference 2.7 events per 100,000 persons) (25). A cross-sectional study on 8275 participants reported one case of acute myocardial infarction (26). Another cross-sectional study on 432 participants who received the Moderna vaccine reported chest pain (1.83%) and syncope (0.93%) (27). Likewise, in another cross-sectional study on 803 participants who had received Pfizer vaccine, chest pain (1.12%) and Syncope (0.12%) were reported as serious adverse events (20). Another cross-sectional study on 190 patients who had received the Pfizer vaccine reported one case of supraventricular tachycardia (1%) and one case of decompensated heart failure (1%) (28). In a 2nd phase RCT on 43,448 participants, 21720 of whom received BNT162b2 vaccine, one case of paroxysmal ventricular tachycardia (0.004%) was reported (29).

-Pregnancy

Among studies included in our review, two studies were conducted on pregnant women who had received mRNA vaccine during their pregnancy, and one study on 35691 pregnant women reported possible serious adverse effects as follows: spontaneous abortion (46 cases; 37 in the first trimester, 2 in the second trimester, and 7 in which the trimester was unknown or not reported), stillbirth, premature rupture of membrane, and vaginal bleeding with 3 reports for each, and no congenital anomalies were documented (30). In another study on pregnant women, the rates of adverse pregnancy outcomes among 133 women who received at least 1 dose of the COVID-19 vaccine in pregnancy were similar to that of unvaccinated pregnant women regarding stillbirth (0.0% vs 0.2%), fetal abnormalities (2.2% vs 2.5%), postpartum hemorrhage (9.8% vs 9.0%), cesarean delivery (30.8% vs 34.1%), small for gestational age (12.0% vs 12.8%), maternal high-dependency unit or intensive care admission (6.0% vs 4.0%), and neonatal intensive care unit admission (5.3% vs 5.0%). In addition, three fetal abnormalities, including spina bifida, ventriculomegaly, and hydronephrosis, were reported. The spina bifida case was diagnosed before the pregnant woman received the first dose of the vaccine. The ventriculomegaly case was diagnosed at 37 weeks gestation and was isolated, with no associated brain abnormalities, as confirmed by fetal brain magnetic resonance imaging. The hydronephrosis was mild, with no associated abnormality at birth (31).

-Allergic

Some studies reported rare allergic adverse events such as swelling of eyelids, severe allergic reaction of eyelids, anaphylactoid reactions, and Angioedema (9, 24, 27, 32, 33). In a cross-sectional study conducted on 700 participants who received Pfizer vaccine, two cases with swelling and severe allergic reaction of eyelids were reported (1). In a similar cross-sectional study on 432 participants who received Moderna vaccine, swelling in the mouth or throat (0.46), asthma exacerbation (0.46%), swelling of lips (0.23%), and anaphylaxis (0.23%) were observed (27). Also, in the 3rd phase RCT among 14,134 white and black USA residents who received
Modern, hypersensitivity reactions were reported in 1.5% of participants (24, 27). Two cross-sectional studies reported allergic reactions in 2.2% (15 out of 688) of participants and two cases of Angioedema (0.4%) (2 out of 474) within 48 hours of vaccine injection, respectively (34, 35).

Between December 14, 2020, and January 18, 2021, based on CDC reports, after vaccination with 9,943,247 Pfizer-BioNTech doses and 7,581,429 Moderna doses in the US (CDC unpublished data, February 2021), the risk of anaphylaxis was 4.7 cases/per-million-dose for Pfizer-BioNTech, and 2.5 cases/per-million-dose for Moderna vaccine. Overall, since late January 2021, CDC reported 66 cases of anaphylaxis, including 47 cases after the Pfizer-BioNTech vaccine and 19 cases after the Moderna vaccine. All these 66 persons were treated in health care settings. The median time to event was 6 minutes (range, <1-45 minutes). Almost all cases recovered in the follow-up and no deaths from anaphylaxis after vaccination with either product were reported (36).

In another cross-sectional study, the authors investigated the adverse effects of 578,835 doses of the mRNA-based vaccines in the Japanese population, 733 Adverse Event Following Immunizations or AEFIls (85 males [12%), 647 females [88%], 1 unknown [1 %]) were reported. Among these, there were 181 (first dose: 177; second dose: 3; unknown: 1) suspected anaphylaxis reports, resulting in a reporting rate of 31.3/100,000 doses. In 171 of 181 cases, women developed suspected anaphylaxis and anaphylactoid symptoms within ≤5 min or >30 min of injection (33).

- Neurologic

In total, 10 studies reported adverse neurologic events among healthy patients and patients with prior neurologic diseases. These adverse events were Bell’s palsy, herpes zoster, ischemic stroke, new or worsening neurologic symptoms (muscle weakness, walking difficulty, gait instability, visual problems, pain, sensorimotor disturbances and sphincteric problems) among patients with underlying neurologic disorders, Guillain-Barre syndrome, seizure, loss of consciousness, fainting, syncope, leg paresthesia, functional syndromes, acute transverse myelitis, and lumbar radiculopathy exacerbation (20, 24-27, 29, 37-40).

A 3rd-phase RCT on 14134 who received Moderna reported three cases of Bell’s palsy in both the vaccine group (<0.1%) and placebo group (<0.1%) (24). In addition, one case of Bell’s palsy was reported 11 days after the 1st dose of Pfizer vaccine in a cross-sectional study. The unadjusted 15-day rate of adverse events per 100,000 residents following the 1st dose of vaccine was the same in both vaccinated and unvaccinated groups for Bell’s palsy (26). Herpes zoster was observed at the rate of 15.8 events per 100,000 persons among 884,828 who received the Pfizer vaccine (25). Other neurological symptoms were as follows: 73 participants (16.7%) who had a history of rare neuro-immunological disorders reported new or worsening neurological symptoms following Pfizer and Moderna vaccination (37), 36 participants (15.1%) with Multiple Sclerosis who received Pfizer COVID-19 vaccine reported new or worsening neurological symptoms (muscle weakness, walking difficulty, gait instability, visual problems, pain, sensorimotor disturbances and sphincteric problems) (41). Guillain-Barre syndrome (GBS) was seen in a healthy male 4 days after the 2nd dose of Moderna (39), there was one case of the seizure (0.23%) after receiving Moderna vaccine (27), food intolerance (0.25%), loss of consciousness or fainting (0.25%), seizures (0.12%), and syncope (0.12%) among 803 participants who had received Pfizer (20), and one case of leg paresis in a 2nd-phase RCT of Pfizer vaccine (29).

In addition, a cohort study on 704,003 participants who received Pfizer vaccine reported 33 (0.005%) serious adverse events, 17 of which (51.5%) were neurologic (2.4/100,000 doses) in the first 30 days after vaccination, however, no death was reported due to the complications. Among those 17 patients, seven cases had seizures (0.99/100,000 doses), four mentioned functional syndromes (0.56/100,000 doses); three had GBS (0.43/100,000 doses); two were diagnosed with acute transverse myelitis (0.28/100,000 doses); and one case was consistent with lumbar radiculopathy exacerbation (0.14/100,000 doses) (40).

- Immunocompromised patients

A retrospective study on 113 allogeneic hematopoietic stem cell transplant recipients who received Pfizer-BioNTech and Moderna vaccine reported one case of axillary lymphadenopathy, one case of increased blood pressure, and tachycardia. In addition, neutropenia, thrombocytopenia, lymphopenia, and eosinophilia were observed in 13.3%, 11.5%, 8.8%, 4.4% of vaccine recipients 20.5, 34, 19.5, and 28 days after vaccination. In addition, they reported new chronic Graft-versus-host disease (GVHD) (9.7%) or worsening chronic GVHD (3.5%) 3 to 48 days after vaccination. Also, two patients experienced both new and worsening GVHD symptoms. One patient with a previous history of chronic GVHD was hospitalized (23). Another study on 80 allogeneic hematopoietic cell transplantation recipients or CD19-based chimeric antigen receptor T-cell (CART) therapy patients who received Pfizer vaccine reported cytopenia (12% of the patients after the 1st dose and 10% of the patients after the 2nd dose), graft-versus-host disease exacerbation (4.5%), and a single case of impending graft rejection as possible vaccination adverse effects within 1st week of injection (42). One cohort study on 741 solid organ transplant recipients who received Pfizer or Moderna vaccines, reported one case of acute rejection after the 2nd dose, and infection (3% after 1st dose and <0.01% after 2nd dose) within 7 days post-vaccination. Lao, in a cohort study that was conducted on 151 cancer patients and 54 healthy patients who received Pfizer or Moderna vaccines, reported only one case
of deranged liver function test 3 weeks after the 1st dose in the control group (43). In a study of 373 cancer patients who received Pfizer-BioNTech or Moderna vaccine, eight patients reported severe adverse events as follows: chest pain (0.3%), dyspnea (1.1%), urosepsis (0.3%), febrile neutropenia (0.3%), and lymphadenopathy (0.5%) within seven days after injection, and venous thromboembolism (VTE) (0.3%) within seven days after vaccination (44).

4. Discussion

In this review, we synthesized the safety data and side effects of COVID-19 vaccines from 74 published articles. It appeared that the adverse reactions were often mild to moderate with few serious adverse events. At least one case of serious adverse events was reported in 30 articles. Most studies had investigated the adverse events after the Pfizer-BioNTech vaccine, while few studies had studied Moderna (mRNA-1273) or both mRNA vaccines’ adverse effects. The number of adverse effects reported after the Pfizer vaccine was higher, but this was mostly due to its earlier approval and more widespread uptake across the world. The reported severe adverse events associated with the COVID-19 vaccines were more frequently related to allergic events, neurological events, and cardiovascular implications including chest pain, myocardial infarction, acute hypertension, tachycardia, myocarditis, syncope, supraventricular tachycardia, decompensated heart failure, and paroxysmal ventricular tachycardia.

The majority of vaccine recipients reported at least one local or systemic side effect after inoculation with the mRNA COVID-19 vaccine. Albeit, all reported side effects were minor and had a short duration. Local and systemic adverse reactions were found to be more prevalent after the second dose. Common adverse reactions were injection site pain, headache, muscle pain, myalgia, chills, and fever. The systemic adverse reactions had moderate intensity in the young age group in comparison with those who were 65 years old or older. The majority of adverse reactions like fatigue, joint pain, muscle pain, and headache were reported by the younger age group (18-55 years) and obviously, less reported by the older adults. These findings are in line with findings of a similar study that assessed 11 clinical trials of COVID-19 vaccines (45).

Ten studies in this review reported possible cardiac adverse effects. In those who received Pfizer vaccine, severe chest pain, acute hypertension, tachycardia, myocarditis, syncope, supraventricular tachycardia, decompensated heart failure, and paroxysmal ventricular tachycardia were reported. On the other hand, increased blood pressure, tachycardia, cardiopulmonary arrest, chest pain, and syncope were reported in Moderna receivers. In addition, acute myocardial infarction was documented after mRNA vaccine inoculation.

No significant association has been found between COVID-19 mRNA vaccines and cardiac adverse events mentioned above, except for myopericarditis. The findings of a systematic review conducted to investigate the safety and adverse events of COVID-19 vaccines among children and adolescents were in line with our findings; 27 cases of approved myopericarditis or pericarditis were found in 7 assessed studies (including one RCT, two case series, and four case reports), all of which occurred after the 2nd dose of Pfizer vaccine. This systematic review’s findings show an incidence rate of 0.008% for myopericarditis in adolescents aged 16 to 17 years old and also 0.01% in adolescents aged 12 through 15 years following the second dose (25, 46).

In another study, 16 cases of myocarditis, pericarditis, and myopericarditis were reported after injection of both types of mRNA vaccines. These severe cardiac adverse effects occurred after the first vaccine dose in six cases (35%), after the second dose in ten cases (59%), and after both doses in one case (6%). The median time to event was 14 days (range 1–28) after the first vaccination and 3 days (range 1–17) after the second shot (47). Similar findings were reported in a systematic review that investigated the cardiac adverse outcomes after COVID-19 vaccine injection. In total, 42 acute myocardial infarction (AMI) and 35 myocarditis cases were reported after COVID-19 vaccination and 41 (98%) and 31 (89%) of these cases had been vaccinated by mRNA vaccines, respectively. The majority were men, and myocarditis cases were younger than AMI patients. Myocarditis was observed after an average of 3 days after vaccination, while AMI mostly occurred after an average of 1 day. Thirty-five (83%) myocarditis and six (33%) AMI patients developed symptoms after their second dose. The majority of the myocarditis (83%) and AMI patients (86%) had received the Pfizer BioNTech vaccine. The remaining patients with myocarditis received the Moderna (14%) and Janssen vaccine (2%) vaccines, while AMI patients had received the Oxford-AstraZeneca vaccine (11%) and Moderna vaccine (3%) (48). These findings were consistent with our study indicating a strong possibility of myocarditis (risk ratio, 3.24; [CI95% 1.55-12.44]) after BNT162b vaccination; however, this risk was significantly lower in comparison with myocarditis after SARS-COV-2 infection, which is 18.28 (95% confidence interval [CI95% 3.95-25.12]) (25). In addition, some included studies in our review had reported cases of severe chest pain and acute myocardial infarction.

It seems that the rate of adverse pregnancy outcomes is no different between vaccinated and unvaccinated pregnant women and no association between mRNA vaccines and pregnancy outcomes was found. This finding was consistent with the findings of other systematic reviews, which were conducted on pregnant women who received either of the mRNA vaccines. No increased risk of adverse obstetrical or neonatal outcomes was reported and the proportion of in-
fant outcomes reported, including spontaneous abortions, stillbirth, induced abortion ectopic pregnancy, and spontaneous abortions, were similar to non-vaccinated pregnant women. Also, safety data indicated that pregnant and lactating populations experienced vaccine-related reactions at similar rates to the general population (49, 50).

The findings of included studies showed that those who have received the Pfizer vaccine are more likely to have allergic reactions than those who received Moderna vaccine. A systematic review including 26 articles, involving 26,337,421 mRNA SARS-CoV-2 vaccine recipients (14,505,399 doses of Pfizer-BioNTech and 11,831,488 doses of Moderna) reported similar results. This study reported that vaccination with Pfizer-BioNTech vaccine resulted in higher rate of anaphylactic reactions compared to Moderna vaccine (9.31/per-million-dose and 3.42/per-million-dose). This study also reports a lower incidence of non-anaphylactic reactions with Pfizer compared to Moderna (75.27/per-million-doses, versus 99.01/per-million-doses administered) (51). In another systematic review and meta-analysis, which investigated the risk of allergic and severe adverse events, the incidence rate of anaphylaxis was reported as 7.91/per-million-cases (among 41,000,000 patients) (52).

The post-COVID-19 vaccination neurological adverse events are relatively rare and the causal association between neurological symptoms and vaccination is uncertain. Bell’s palsy was reported as one of the neurological adverse events in two assessed studies (26, 53). However, no significant differences in Bell’s palsy incidence were reported between vaccinated and unvaccinated individuals. A review has also acknowledged that most Bell’s palsy cases were associated with mRNA vaccines. No difference was found between clinical features of vaccine-associated Bell’s palsy and conventional types and the pathogenesis remains unclear (54). In addition, some neurological adverse events including Guillain-Barre syndrome, herpes zoster, seizure, loss of consciousness or fainting, syncope, leg paresthesia, and acute transverse were reported; the causal association of adverse events and vaccination or coincidence of them must be carefully assessed.

Most of the COVID-19 vaccine randomized trials have excluded those with immunocompromised conditions, so there is limited data available about adverse events in individuals with autoimmune disease and cancer. However, in transplant recipients, graft-versus-host disease exacerbation, and impeding graft rejection were reported as possible vaccination adverse events. No significant difference was reported between severe complications in cancer patients and healthy patients, as the control group, who received Pfizer or Moderna vaccines (43, 44).

The adverse events of vaccination should continuously be monitored to identify any new issues in the safety of vaccines, which require investigations. In other words, while assessing the safety of vaccines, any unexpected or unusual patterns in vaccinated individuals, which have a higher rate than the general population should be considered. In this study, the most commonly reported serious adverse events were cardiac events, additional studies are recommended to investigate the association between vaccination and cardiac complications. Also, in order to collect data on the clinical, cardiological, neurological, and immunological profile of the COVID-19 vaccinated population, cohort studies could further assess the frequency of adverse events in the general population.

5. Conclusion

Some severe adverse events were observed among the recipients of mRNA vaccines, but a direct relationship between the vaccines and adverse events has not been clearly established for the adverse events, except for myopericarditis. The rate of severe adverse effects is low and obviously, the benefits of receiving vaccines in preventing severe COVID-19 and death outweigh the possible rare adverse events of the COVID-19 vaccines. Therefore, healthcare officials should enlighten people on the safety of the vaccines, in this case mRNA vaccines, to avoid further hesitations in COVID-19 vaccination, which may endanger the lives of people and pose a huge burden on the healthcare system.

6. Declarations

6.1. Acknowledgments

This systematic review was supported by Tehran University of Medical Sciences with the grant no. 1400-3-119-55855 and the ethics code: IR.TUMS.IKHC.REC.1400.510.

6.2. Data availability

The data is at the disposal of the corresponding author of the article and it it can be made available to the researchers upon request.

6.3. Authors’ contributions

(1) The conception and design of the study: Esmaeil Mehraeen, SeyedAhmad SeyedAlinaghi
(2) Acquisition of data: Amirali Karimi, Zahra Pashaei
(3) Analysis and interpretation of data: Pegah Mirzapour, Arian Afzalian
(4) Drafting the article: Kobra Ghorbanzadeh, Afsaneh Ghasemzadeh, Mohsen Dashti, Newsa Nazarian, Farzin Vahedi, Marcarious M. Tantuoyir, Ahmadreza Shamsabadi
(5) Revising it critically for important intellectual content: SeyedAhmad SeyedAlinaghi, Omid Dadras
(6) Final approval of the version to be submitted: all authors

This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Downloaded from: http://journals.sbmu.ac.ir/aaem
6.4. Funding and supports
This research received a grant from Tehran University of Medical Sciences (Grant no. 1400-3-119-55855).

6.5. Competing interests
The authors declare that there is no conflict of interest regarding the publication of this manuscript.

6.6. Availability of data and material
The authors stated that all information provided in this article could be shared.

6.7. Consent to publication
Not applicable

6.8. Ethics approval and consent to participate
The present study was approved by Tehran University of Medical Sciences with the ethics code: IR.TUMS.IKHC.REC.1400.510.

References

1. Amimo F, Lambert B, Magit A, Hashizume M. A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa. Globalization and health. 2021;17(1):42.

2. Gubernto D, Jazwa A, Niu M, Baumbllatt J, Gee J, Moro P, et al. U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines. Vaccine. 2021;39(28):3666-77.

3. Dadras O, Alinaghi SAS, Karimi A, MohsseniPour M, Barzegary A, Vahedi F, et al. Effects of COVID-19 prevention procedures on other common infections: a systematic review. European journal of medical research. 2021;26(1):67.

4. Joshi RK, Muralidharan CG, Gulati DS, Mopagar V, Dev JK, Kuthe S, et al. Higher incidence of reported adverse events following immunisation (AEFI) after first dose of COVID-19 vaccine among previously infected health care workers. Medical journal, Armed Forces India. 2021;77(Suppl 2):S505-s7.

5. Bukhari MH, Syed M, Zain S. The Differences between Traditional Vaccines and RNA Vaccines: Safety, Efficacy, Reliability and Future of COVID-19 Vaccines. Annals of King Edward Medical University Lahore Pakistan. 2021;27(2):172-82.

6. Klugar M, Riad A, Mekhemar M, Conrad J, Buchbender M, Howaldt HP, et al. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers. Biology. 2021;10(8):752.

7. Organization WH. 10 Vaccines Approved for Use by WHO: WORLD HEALTH ORGANIZATION (WHO); 2021 [updated 22 December 2021; cited 2021 23 December ]. Available from: https://covid19.trackvaccines.org/agency/who/.

8. Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndez A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. Frontiers in immunology. 2021;12:701501.

9. Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batinhe Y, Dahham AT, et al. Safety of COVID-19 vaccines. Journal of medical virology. 2021;93(12):6588-94.

10. Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S, et al. Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia. Vaccines. 2021;9(6).

11. Coggins SAA, Laing ED, Olsen CH, Goguet E, Moser M, Jackson-Thompson BM, et al. Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers. medRxiv : the preprint server for health sciences. 2021.

12. Botwin GJ, Li D, Figueiredo J, Cheng S, Braun J, McGovern DPB, et al. Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease. The American journal of gastroenterology. 2021.

13. Cirillo N. Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns. Journal of oral pathology medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2021;50(4):424-7.

14. MacIntyre CR, Veness B, Berger D, Hamad N, Bari N. Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - A risk-benefit analysis for people < 60 years in Australia. Vaccine. 2021;39(34):4784-7.

15. Manzo C, Natale M, Castagna A. Polymyalgia rheumatica as uncommon adverse event following immunization with COVID-19 vaccine: A case report and review of literature. Aging medicine (Milton (NSW)). 2021;4(3):234-8.

16. Park C, Sakong J, Jo S, Kim M, Baek K. Adverse Effects on Work and Daily Life Interference among Healthcare Workers after the First and Second ChAdOx1 and BNT162b2 COVID-19 Vaccine Doses. Vaccines. 2021;9(8).

17. Karayeve E, Kim HW, Bandy U, Clyne A, Marak TP. Monitoring Vaccine Adverse Event Reporting System (VAERS) Reports Related to COVID-19 Vaccination Efforts in Rhode Island. Rhode Island medical journal (2013). 2021;104(7):64-6.

This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).
Downloaded from: http://journals.shmu.ac.ir/aaem
41. Lotan I, Will-Yarkoni A, Friedman Y, Stiebel-Kalish H, Steiner I, Hellmann MA. Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. European journal of neurology. 2021;28(11):3742-8.

42. Ram R, Hagin D, Kikozashvili N, Freund T, Amit O, Bar-On Y, et al. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy: A Single-Center Prospective Cohort Study. Transplantation and cellular therapy. 2021;27(9):788-94.

43. Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. The Lancet Oncology. 2021;22(6):765-78.

44. So ACP, McGrath H, Ting J, Srikandarajah K, Germanou S, Moss C, et al. COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. Cancers. 2021;13(14).

45. Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhintra S, Mitra P, et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian J Clin Biochem. 2021;36(4):1-13.

46. Lv M, Luo X, Shen Q, Lei R, Liu X, Liu E, et al. Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review. Vaccines. 2021;9(10).

47. Garg RK, Paiival VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022;43(1):3-40.

48. Kozlovskaia LI, Piniaev AN, Ignatyev GM, Gordeychuk IV, Volok VP, Rogova YV, et al. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerging microbes & infections. 2021;10(1):1790-806.

49. Abu-Halawehe S, Alqassieh R, Suleiman A, Al-Sabagh MQ, AbuHalawehe M, AlKhader D, et al. Qualitative Assessment of Early Adverse Effects of Pfizer-BioNTech and Sinopharm COVID-19 Vaccines by Telephone Interviews. Vaccines. 2021;9(9):950.

50. Abu-Hammad O, Aldouraithi H, Abu-Hammad S, Alnazarwai A, Babkair H, Abu-Hammad A, et al. Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. Vaccines. 2021;9(6):577.

51. Alomari MA, Al Mutair A, Al Alawi Z, Rabaaan AA, Tirupathi R, Alhumaid S, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021;17(1):109.

52. Greenhawt M, Abrams EM, Shaker M, Chu DK, Khan D, Akin C, et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract. 2021;9(10):3546-67.

53. Li X, Ostropolets A, Makadia R, Shouab A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: Multinational network cohort study. The BMJ. 2021;373.

54. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Al Ghafri TS, Al Balushi L, Al Hinai F, Al Halawani S, Anwar H, et al. Reporting at Least One Adverse Event Post-COVID-19 Vaccination From Primary Health Care in Muscat. Cureus. 2021;13(8):e17055.

55. Li X, Ostropolets A, Makadia R, Shouab A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: Multinational network cohort study. The BMJ. 2021;373.

56. Wilson AP, McGrath H, Ting J, Srikandarajah K, Germanou S, Moss C, et al. COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. Cancers. 2021;13(14).

57. Garg RK, Paiival VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022;43(1):3-40.

58. Abu-Halawehe S, Alqassieh R, Suleiman A, Al-Sabagh MQ, AbuHalawehe M, AlKhader D, et al. Qualitative Assessment of Early Adverse Effects of Pfizer-BioNTech and Sinopharm COVID-19 Vaccines by Telephone Interviews. Vaccines. 2021;9(9):950.

59. Abu-Hammad O, Aldouraithi H, Abu-Hammad S, Alnazarwai A, Babkair H, Abu-Hammad A, et al. Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines. Vaccines. 2021;9(6):577.

60. Al Ghafri TS, Al Balushi L, Al Balushi Z, Al Hinai F, Al Hasani S, Anwar H, et al. Reporting at Least One Adverse Effect Post-COVID-19 Vaccination From Primary Health Care in Muscat. Cureus. 2021;13(8):e17055.

61. Al Omari MA, Al Mutair A, Al Alawi Z, Rabaaan AA, Tirupathi R, Alhumaid S, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021;17(1):109.
62. Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021;27(12):1851-5.

63. Li J, Hui A, Zhang X, Yang Y, Tang R, Ye H, et al. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nature medicine. 2021;27(6):1062-70.

64. Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ (Clinical research ed). 2021;373:n1435.

65. Ligumsky H, Safadi E, Etan T, Vaknin N, Waller M, Croll A, et al. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients. Journal of the National Cancer Institute. 2022;114(2):203-9.

66. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet (London, England). 2021;398(10303):856-69.

67. Maeda K, Amano M, Uemura Y, Tsuchiya K, Matsushima T, Noda K, et al. Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals. medRxiv : the preprint server for health sciences. 2021.

68. Mascellino MT, Di Timoteo F, De Angelis M, Oliva A, et al. Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infection and clinical medicine. 2021;10(7).

69. Massoud F, Ahmad SF, Hassan AM, Alexander KJ, Al-Hashel I, Arabi M. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study. Seizure. 2021;32:2-9.

70. Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP, et al. Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey. Life (Basel, Switzerland). 2021;11(3):249.

71. McMurry R, Lenehan P, Awasthi S, Silvert E, Puranik A, Pawlowski C, et al. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med (New York, NY). 2021;2(8):965-78.e5.

72. Menni C, Klasen K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious diseases. 2021;21(7):939-49.

73. Modenes e A, Paduano S, Bargellini A, Bellucci R, Marchetti S, Bruno F, et al. Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart. Vaccines. 2021;9(6):652.

74. Hall VG, Ferreira VH, Ierullo M, Ku T, Marinelli T, Majchrzak-Kita B, et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2021;21(12):3980-9.

75. Hatmal MM, Al-Hatamleh MAI, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, et al. Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. Vaccines. 2021;9(6):556.

76. Kim T, Park SY, Yu S, Park JW, Lee E, Jeon MH, et al. Impacts of Side Effects to BNT162b2 and the First Dose of ChAdOx1 Anti-SARS-CoV-2 Vaccination on Work Productivity, the Need for Medical Attention, and Vaccine Acceptance: A Multicenter Survey on Healthcare Workers in Referral Teaching Hospitals in the Republic of Korea. Vaccines. 2021;9(6):648.

77. Riad A, Pokorná A, Attia S, Klugarová J, Košćík M, Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. Journal of clinical medicine. 2021;10(7).

78. Rechavi Y, Shashar S, Lellouche J, Vana M, Yukubovich D, Sharon N. Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response. Vaccines. 2021;9(9):977.

80. Quiroga B, Sánchez-Álvarez E, Goicochea M, de Sequer a P. COVID-19 vaccination among Spanish nephrologists: Acceptance and side effects. Journal of healthcare quality research. 2021;36(6):363-9.

81. Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falucchini P, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative
malignancies on active treatment: preliminary data from a single institution. Journal of hematology & oncology. 2021;14(1):81.

82. Panda DS, Giri RK, Nagarajappa AK, Basha S. Covid-19 vaccine, acceptance, and concern of safety from public perspective in the state of Odisha, India. Human vaccines & immunotherapeutics. 2021;17(10):3333-7.

83. Ou MT, Boyarsky BJ, Motter JD, Greenberg RS, Teles AT, Ruddy JA, et al. Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation. 2021;105(10):2170-4.

84. Oh HK, Kim EK, Hwang I, Kim TE, Lee YK, Lee E, et al. COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021. Osong public health and research perspectives. 2021;12(4):264-8.

85. Morales-Núñez JJ, Muñoz-Valle J, Meza-López C, Wang LF, Machado Sulbarán AC, Torres-Hernández PC, et al. Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection. Vaccines. 2021;9(7):742.

86. Tissot N, Brunel AS, Bozon F, Rosolen B, Chirouze C, Bouiller K. Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine. Vaccine. 2021;39(36):5087-90.

87. Zitt E, Davidovic T, Schimpf J, Abbassi-Nik A, Mutschlechner B, Ulmer H, et al. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients. Frontiers in immunology. 2021;12:704773.

88. Xiong X, Yuan J, Li M, Jiang B, Lu ZK. Age and Gender Disparities in Adverse Events Following COVID-19 Vaccination: Real-World Evidence Based on Big Data for Risk Management. Frontiers in medicine. 2021;8:700014.

89. Wi YM, Kim SH, Peck KR. Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers. Vaccines. 2021;9(8):931.

90. El-Shitany NA, Harakeh S, Badr-Eldin SM, Bagher AM, Eid B, Almuakdi H, et al. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study. International journal of general medicine. 2021;14:1389-401.

91. French RW, Jr., Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. The New England journal of medicine. 2021;385(3):239-50.

92. Golan Y, Prahl M, Cassidy AG, Gay C, Wu AHB, Jigmeddagy U, et al. COVID-19 mRNA Vaccination in Lactation: Assessment of adverse effects and transfer of anti-SARS-CoV2 antibodies from mother to child. medRxiv: the preprint server for health sciences. 2021.
| First Author Country | Study type | Manufacturer* | Sample | Age | Gender (%) | Severe adverse event | Time to appearance | Side effects (%) |
|----------------------|------------|---------------|--------|-----|------------|----------------------|-------------------|------------------|
| Tom T. Shimabukuro (55) USA/White | Cross-sectional | PB, M | 35,691 | 16 to 54 years | Female (100) | Spontaneous abortion, Preterm birth, small size for gestational age | N/A | Injection-site pain, Headache, Myalgia, Chills, and fever |
| Abu-Halaweh, S. (56) USA | Observational cohort | PB | 491 | >70 years | Male (67) Female (33) | N/A | N/A | Injection site pain, Muscle pain |
| Abu-Hammad, O. (57) USA | Cross-sectional | PB | 409 | N/A | N/A | No severe adverse reaction | 1.39 ± 1.12 days | Injection site pain or arm numbness, Fatigue, Myalgia, Headache |
| Al Ghafri, T. S. Oman | Cross-sectional | PB | 753 | 62 | Males (54.1), Female (45.9) | No severe adverse reaction | 2 days | Pain and tenderness, Fever and body aches |
| Al Khamis Aga, Q. A. (9) USA | Cross-sectional | PB | 700 | 18 and above | Male (51.6), Female (48.4) | Tenderness or swollen lymph nodes, severe allergic reaction of eyelids, severe chest pain, acute hypertension, acute hyperglycemia | 1.90±2.128 days | Pain, Redness, Urticarial, and swelling at the site of the injection, Fatigue, body Pain, Headache, Muscle Pain, Fever, and gastrointestinal effects |
| Alhazmi, A. (10) Saudi Arabia | Cross-sectional | PB | 533 | 18 to 70 years | Male (45), Female (57) | Hospitalization due to side effect | 1-5 days | Pain, and redness at the site of injection, Fatigue, Fever, Chills, and headache |
| Ali, H. (23) USA | Retrospective study | PB | 113 | 66.5 | Male (69), Female (31) | Axillary lymphadenopathy, Increased blood pressure, and tachycardia | 26 days | Injection site pain, Injection-site rash, and swelling, Myalgia, Arthralgia, Fatigue, Nausea, Vomiting, Diarrhea, and headache |
| Anderson, E. J. (59) USA | RCT First phase | M | 40 | 56-70 | Male (48), Female (52) | Paronychia | 2 days | Injection-site pain, Headache, Fatigue, Fever, Myalgia, and chills, |
| Andrzejczak-Grzadko, S. (18) Poland | Cross-sectional | PB | 196 | 20-84 | Male (15), Female (85) | Enlarged lymph nodes, decreased alcohol tolerance | N/A | Injection site pain, Shoulder pain, Muscle aches, Neck pain, and hand numbness, Headache, Fever, Chills, Nausea, Vomiting, Drowsiness, Diarrhea, and dizziness |
| Baden, L. R. (24) USA/White and black | RCT Third phase | M | 14134 | 51.4 | Male (52.7), Female (47.3) | Cardiopulmonary arrest, Bell's palsy | N/A | Injection site pain, Erythema, Induration, and tenderness, N/A |
| Barda, N. (25) USA | RCT | PB | 884828 | 36 | Male (52), Female (48) | Myocarditis, Lymphadenopathy, Appendicitis, Arrhythmia, Deep-vein thrombosis, Myocardial infarction, Myocardial Infarction, intracranial hemorrhage, pulmonary embolism, herpes zoster | N/A | N/A | Vertigo |
| First Author Country | Study type | Manufacturer* | Sample | Age | Gender (%) | Severe adverse event | Time to appearance | Side effects (%) |
|----------------------|------------|---------------|--------|-----|------------|---------------------|-------------------|------------------|
| Bardenheier, B. H. (26) USA/white, black | Cross-sectional | PB | 8275 | 18 and above | Male (38.1), Female (61.9) | Acute Myocardial Infarction, Bell’s Palsy, Stroke, ischemic, Venous thromboembolism, and Pulmonary Embolism | 15-day | N/A | N/A |
| Benda, M. (60) Austria | Cross-sectional | PB | 259 | 65.1 | Male (57.5), Female (42.5) | No severe adverse reaction | 7-day | Injection site pain | Fatigue, Severe headache, Severe general muscle pain, and fever |
| Blakeway, H. (31) UK/ Afro-Caribbean, Asian ethnicity, and White | Retrospective cohort study | PB, M | 1328 | 18-40 | Female (100) | Spina bifida, Ventriculomegaly, hydronephrosis, fetal abnormalities, postpartum hemorrhage | N/A | N/A | N/A |
| Caminati, M. (61) Italy | Cross-sectional | N/A | 253 | N/A | N/A | No severe adverse reaction | N/A | N/A | N/A |
| Levy I. (62) Israel | Prospective study | PB | 143 | 49.8±11.5 years | Male and female | N/A | 21 days | Local pain, Fatigue, headache, fever |
| Li J. (63) UK | RCT | PB | 463 | 57.8±4.7 years | Male (54) Female (46) | N/A | 28 days and 84 days | Mild to moderate pain at the injection site, injection-site redness, or swelling | Fever, fatigue, headache, gehad, and muscle and joint pain |
| Li J. (32) China | Prospective study | N/A | N/A | N/A | Anaphylactic reaction (1/100000) | N/A | Pain at the injection site, injection-site redness or swelling | Fever, fatigue, headache, and muscle and joint pain |
| Li X. (64) UK | Cohort study | N/A | 126661070 | N/A | Male (49.5) Female (50.5) | Hemorrhagic and non-hemorrhagic stroke, pulmonary embolism, Bell’s palsy, immune thrombocytopenia, Guillain-Barre syndrome, and disseminated intravascular coagulation | N/A | N/A | N/A |
| Ligumsky H. (65) Israel | Retrospective cohort study | PB | 326 | 66 | Male (37.7) Female (62.3) | N/A | 40 days | Local pain (n = 64, 19.6%) | Weakness (17.5) Myalgia (12.6) Headache (6.4) |
| Liu X. (66) China | RCT | First phase | PB | 296 | 5I | Male (16.4) Female (83.6) | N/A | 7 days after the 1st or 2nd dose Pain, Redness, Swelling, Induration | Headache, Fatigue, Joint pain, Muscle pain, Chills, Nausea, Anorexia, Diarrhea, Vomiting |
Table 1: Severe adverse events, local and systemic side effects of mRNA COVID-19 vaccination

| First Author | Country | Study type                      | Manufacturer* | Sample | Age | Gender (%) | Severe adverse event                                      | Time to appearance | Side effects (%)                       |
|--------------|---------|---------------------------------|---------------|--------|-----|------------|----------------------------------------------------------|-------------------|----------------------------------------|
| Lotan I. (37) USA | Cross-sectional | PB, M | 438 | 51 | Male (16.4) Female (83.6) | New or worsening neurological symptoms | N/A | Local reactions, including pain, redness, swelling at the injection site |
| Lotan I. (41) Israel | Cross-sectional | PB | N/A | 42 | Male (24) Female (76) | New or worsening neurological symptoms (Muscle weakness, Walking difficulty, Gait instability, Visual problems, Pain, Sensory disturbances, Sphincteric problems) | N/A | Pain/redness/swelling at the injection site | Generalized muscle pain, headache, dizziness, fever, chills, fatigue, |
| Maeda K. (67) Japan | Present prospective observational study | PB | 225 | 41.8 | Male (30.2) Female (69.8) | | N/A | 28 days | Site pain | Systemic fever, headache, and fatigue |
| Marsellino MT. (68) Brazil | Cross-sectional | PB, M | 9000 | N/A | Male (55) Female (45) | | N/A | 28 days | A small pinched pain at the injection site, a little bit of redness | Fatigue, headache, muscle, and joint pain, and fever |
| Massoud F. (69) Kuwait | Cross-sectional | N/A | 111 | N/A | N/A | N/A | N/A | Pain at the injection site (43.8) | Fatigue (46.9), Headache (34.4), Myalgia (50) |
| Matarneh AS. (39) Qatar | Cross-sectional | PB, M | N/A | N/A | N/A | Guillain-Barre syndrome | 4 days | N/A | Upper extremity weakness and numbness four days following the vaccine. |
| Mathioudakis AG. (70) UK | Cross-sectional | PB, M | 532 | 45 | N/A | N/A | N/A | Pain, swelling, tenderness, redness, itching, or other | Fever, skin rash, shortness of breath, tingling in the mouth, face, body/extremities, swelling in the face or mouth, generalized swelling, anaphylaxis, tiredness or fatigue, flu-like illness |
| McMurry R. (71) USA | Cohort study | PB, M | 31029 | N/A | N/A | N/A | N/A | Within 7, 14, 21 days | Local pain and swelling | Fatigue, fever, chills, myalgia, arthralgia, headache, lymphadenopathy, erythema, diarrhea, vomiting, Facial paralysis, |

This open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0). Downloaded from: http://journals.sbmu.ac.ir/naem
| First Author | Study type          | Manufacture* | Sample | Age | Gender (%) | Severe adverse event | Time to appearance | Side effects (%)                                                                 |
|--------------|---------------------|--------------|--------|-----|------------|----------------------|--------------------|--------------------------------------------------------------------------------|
| Menni C.    | Prospective observational study | PB           | 1607620 | 50-6| Male (38-4) Females (61-6) | N/A                  | Within 8 days       | Pain, Swelling, Tenderness, Itch, Swollen armpit glands, Redness, Warmth, Bruising, rash, skin burning, Arthralgia, Myalgia, Nausea, red welts on face and lips |
| Modenese A. | Observational study | PB           | 76     | 48.4| Males (19) Females (81) | N/A                  | 4 weeks             | Pain sensation at the injection site 73.6% redness in the injection site Asthenia and sleepiness, chills, 32%, myalgia and arthralgia, 31% for headache/ migraine, and 18% for fever, diarrhea, erythema, abdominal pain, itch, and vertigo |
| Hall VG     | Prospective study | M            | 127    | 66.2| Male (69.3) Female (30.7) | Varicella Zoster Virus reactivation (0.78%), Fever and pruritic rash (0.78%), hospitalization (0.78%) | Within 7 days       | Pain, erythema, swelling Fever, headache, fatigue, myalgia, arthralgia, chills, |
| Hatmal MM   | Cross-sectional PB, M | 612          | 18 and above | N/A | N/A                     | Seizures (0.23%), chest pain (1.85%), syncope (0.93%), swelling in the mouth/throat (0.46%), asthma exacerbation (0.46%), swelling of lips (0.23%), anaphylaxis (0.23%) | Within 4h to three days | Pain, swelling, itching, rash, lymphadenopathy, skin discoloration, bleeding, Weakness, headache, chills, fever, sweating, dizziness, flushing, Myalgia, arthritis, muscle stiffness/spasm, Nausea, decreased appetite, diarrhea, abdominal pain, heartburn, vomiting, constipation, swallowing, decreased sleep quality, anxiety, decrease in memory, depression, manic mood changes, psychological stress, brain fogging or confusion, incoordination, extremity weakness, fainting, seizures, herpes or shingle-like lesions, eye pain, runny nose, ringing sensation in the ears, ear pain, blurred vision, flashing lights, changes in hearing, double vision, nose bleed, bleeding gums, hoarseness, Palpitations heart, blood pressure changes, chest pain, |
| Kadali RAK. | Cross-sectional | M            | 432    | 18-80 years old | Male (10.4) Female (89.6) | Seizures (0.23%), chest pain (1.85%), syncope (0.93%), swelling in the mouth/throat (0.46%), asthma exacerbation (0.46%), swelling of lips (0.23%), anaphylaxis (0.23%) | N/A                | Pain, swelling, itching, rash, lymphadenopathy, skin discoloration, bleeding, Weakness, headache, chills, fever, sweating, dizziness, flushing, Myalgia, arthritis, muscle stiffness/spasm, Nausea, decreased appetite, diarrhea, abdominal pain, heartburn, vomiting, constipation, swallowing, decreased sleep quality, anxiety, decrease in memory, depression, manic mood changes, psychological stress, brain fogging or confusion, incoordination, extremity weakness, fainting, seizures, herpes or shingle-like lesions, eye pain, runny nose, ringing sensation in the ears, ear pain, blurred vision, flashing lights, changes in hearing, double vision, nose bleed, bleeding gums, hoarseness, Palpitations heart, blood pressure changes, chest pain, |
| First Author Country | Study type | Manufacturer* | Sample | Age | Gender (%) | Severe adverse event | Time to appearance | Side effects (%) |
|----------------------|------------|---------------|--------|-----|------------|---------------------|-------------------|------------------|
| Renuka A.K. Kadali. (20) USA | Cross-sectional | PB | 803 | 18-90 years old | Male (13.4) Female (86.6) | Food intolerance (0.25%), Loss of consciousness/fainting (0.25%), Seizures (0.12%), Chest pain (1.12%), Syncope (0.12%) | N/A | Sore arm/pain, swelling at the injection site, Itching, Lymphadenopathy, Rash, skin discoloration, Bleeding, Loss of hair locally. |
| Kim T. (76) Republic of Korea | Cross-sectional | | 2574 | 20 to ≥60 | Male (24.7) Female (75.2) | none | <3 hour-≥48 hour | Local tenderness/erythema/ heating sensation, edema. General myalgia, febrile sensations, chills, fatigue, rash, headache, Arthralgia, Dizziness, Nausea, vomit, pruritus, dyspnea. |
| Miloslav Kluger. (35) Czech Republic | Cross-sectional | PB, M | 474 | N/A | Male (25.7) Female (73.6) Unknown (0.6) | Severe side effects (0.4%), Angioedema (0.4%) | N/A | Injection site pain, injection site swelling, injection site redness, ulcers, vesicles, blisters, angular cheilitis, white/red plaque, oral paresthesia, taste disturbance, halitosis, bleeding gingiva, swollen mucosa, rash, Urticarial, angioedema. |
| Iguchi, T. (33) Japan | Cross-sectional | PB | 578,835 doses and 733 adverse events | 22-56 years old | Male (12) Female (88) | 181 cases of Anaphylaxis and anaphylactoid symptom | ≤5min >30min | N/A | Anaphylaxis and anaphylactic symptoms. |
### Table 1: Severe adverse events, local and systemic side effects of mRNA COVID-19 vaccination

| First Author Country | Study type | Manufacturer* | Sample | Age | Gender (%) | Severe adverse event | Time to appearance | Side effects (%) |
|----------------------|------------|----------------|--------|-----|------------|----------------------|-------------------|-----------------|
| A. Riad. (77) Czech Republic/South Moravian | Cross-sectional | PB | 877 | 43 | Male (11.6) Female (88.4) | N/A | 1-3 days | Injection site pain and redness, labial blisters, plaque, bleeding gingiva, halitosis, lymphadenopathy |
| A. Riad. (78) Slovakia/Slovak | Cross-sectional | PB | 522 | 37.7±11 | Male (23) Female (77) | N/A | 1-3 | Injection site pain, swelling, and redness, oral side effects, lymphadenopathy |
| Y. Rechavi. (79) Israel/Arabs | Cohort study | PB | 136 | 40.09 | Male (34) Female (66) | N/A | N/A | Injection site pain, swelling, and redness |
| R. Ram. (42) Israel/Arabs | Cohort study | PB | 80 | 65 | Male (55) Female: (45) | GVHD exacerbation (4.5%) | 1st week | Vasculitis rash on the leg after allogegenic HCT, arthralgia, Cytopenia, fascicilis, humoral or cellular response |
| B. Quiroga. (80) Spain/European | Cohort study | PB | 708 | 44±11 | Male (35) Female (65) | N/A | N/A | A local reaction followed by Myalgia |
| K. Polewska. (28) Poland/Jewish | Cross-sectional | PB | 190 | 68 | Male (64.7) Female: (35.3) | Supraventricular arrhythmia (n=2), COVID after 1st dose (n=2), COVID after 2nd dose (n=3), Pneumonia (n=1), dialysis peritonitis (n=1), catheter infection (n=1), deterioration of glycemic control (n=2), decompensated heart failure (n=1) | 7 days for local 1-3 days systemic 30days for severe adverse effects | Local site reaction, pain, shoulder pain, sinusitis |
| F. Polack. (29) 152 sites worldwide/White, Black or African American, Hispanic or Latinx | RCT Second phase | PB | 43,448 | 52 all >16 | Male (51) Female (49) | Shoulder injury, right axillary lymphadenopathy, paroxysmal ventricular arrhythmia, right leg paresthesia | 7 days for local | Injection site pain (1 severe), redness, swelling, lymphadenopathy |
| E Pimpinelli. (81) Italy/European | Cohort study | PB | 92 | N/A | Male (53.3) Female (46.7) | N/A | N/A | Pain, tenderness |
| M. I. Parvej. (34) Bangladesh/Indo-Aryan | Cross-sectional | N/A | 1529 | 18 and above | Male (66) Female (34) | Thrombosis (0.15%) Allergy (2.2%) | 2 days | Pain in the injection site, Fever,Muscle Pain, headache, allergy, itching, diarrhea |
| First Author Country | Study type        | Manufacturer* | Sample | Age       | Gender (%) | Severe adverse event                      | Time to appearance | Side effects (%)                                      |
|----------------------|-------------------|---------------|--------|-----------|------------|------------------------------------------|--------------------|-------------------------------------------------------|
| A. Park. (16) Korea/Asian | Cross-sectional   | PB            | 27368 | 20 and above | Male (16) Female (90) | Dyspnea (0.025) | 24 hrs | Pfizer(first dose): Local pain Pfizer(second dose): Local pain Pfizer(first dose): Fever, Chills, Myalgia, Headache, Nausea, Vomiting |
| D. S. Panda. (82) India/Indo-Aryan | Cross-sectional   | N/A           | 29    | 18 and above | Male (68.8) Female (31.2) | N/A | N/A | N/A | Fever, Headache |
| M. T. Ou. (83) USA | Prospective cohort | M             | 741   | 60 | Male (43) Female (57) | acute rejection of graft after 2nd dose (0.1%) Infection (after 1st dose (0.4%) and after 2nd dose (0.1%)) | <7 days | pain in injection site fatigue, headache |
| Oh HK. (84) Korea/Asian | Retrospective study | PB            | 35868 | N/A | N/A | N/A | N/A | N/A | Myalgia, fever, headache |
| J. Morales-Nunez. (85) Mexico/Hispanic | Cohort study      | PB            | 303   | 45±12 | Male (40.9) Female (59.1) | N/A | N/A | Rhinorrhea, dysgeusia, chest pain Myalgia, shivers, arthralgia, fever, irritability, odynophagia, cough, headache, diarrhea |
| L. Monin. (43) UK/White and Black | Cohort study      | PB            | 205   | 73 cancer 40.5 healthy | Male (52) Female (48) | Deranged liver function test grade 4 (0.5%) | 3 weeks after 1st dose | Injection site pain, erythema, swelling, lymphadenopathy Flu like symptoms, fatigue, headache, chills, arthralgia, nausea or vomiting, fever, diarrhea |
| Noémie Tissot. (86) France | Prospective cohort | PB            | 311   | 55.4 ± 6.4 | Male (40) Female (60) | N/A | Between 21 and 28 days | Injection site symptoms pain and erythema | Fever chills joint pain Fatigue muscle pain headache |
| Emanuel Zitt. (87) Austria | Cohort study      | PB            | 50    | 67.6 ± 14 | Male (68) Female (32) | N/A | 7 days | Pain | Fever chills joint pain Fatigue muscle pain headache |
| Xiaomo Xiong. (88) USA | Cohort study      | PB, M         | 8,976 | 18-44 years | Male (21.4) Female (78.6) | Death (2.7%), Life-threatening illness (2.7%), Permanent Disability (1%), Hospitalizations (7.1%) | 7 days | Injection site pain | Pyrexia chills Dizziness Fatigue Nausea Headache Pyrexia, pain in extremity, Dyspnea |
| Wi YM. (89) Korea | Cohort study      | PB            | 80    | 35.83 ± 10.99 | Male (31) Female (69) | N/A | After the first and second week | Pain, redness/swelling Lymphadenopathy | Vomiting, nausea, fatigue, chills, fever, myalgia, arthralgia |
| Werbel WA. (90) USA | Cohort study      | PB, M         | 12    | 57 | Male (55) Female: (45) | N/A | 14 days | Pain, redness/swelling | Fatigue, chills, fever, myalgia, diarrhea, headache |
| Edward E. Walsh. (91) USA | RCT First phase | PB            | 195   | 35 | Male (42) Female (58) | N/A | 7 days | Pain, redness/swelling | Fever, fatigue, chills |
Table 1: Severe adverse events, local and systemic side effects of mRNA COVID-19 vaccination

| First Author               | Country          | Study type         | Manufacturer* | Sample | Age | Gender (%) | Severe adverse event                                      | Time to appearance | Side effects (%)                        |
|----------------------------|------------------|--------------------|----------------|--------|-----|------------|----------------------------------------------------------|--------------------|----------------------------------------|
| Alfred Chung Pui So.       | UK               | Retrospective cohort | PB, M         | 373    | 56  | Male (37.5) Female (62.5) | chest pain(0.3%), Dyspnea(1.1%), Urosepsis(0.3%), VTE(0.3%) | 7 days            | Pain at injection site/Sore arm, Erythema |
| Novena Skroza.             | USA              | Cohort study       | PB             | 436    | 57.26 | Male (60) Female (40) | N/A | 10 days      | Pain, redness/swelling                  |
| Tom T. Shimabukuro.        | USA              | Cohort study       | PB, M         | 35,691 | 27.43 | Female 100 | N/A | 14 days After | Pain, redness/swelling Vomiting, Nausea, Fatigue, Chills, Fever, Myalgia, Arthralgia, Diarrhea, Rash |
| Cinzia Rotondo.            | Italy            | Cohort study       | PB, M         | 325    | 60.2 ± 14.2 Female (58) | N/A | 4 days after vaccination | Pain, redness/swelling Chills, Fever, Myalgia, Headache, Nausea |
| Yu-Wei Chen.              | USA              | Cohort study       | PB, M         | 81     | 70  | Male (60) Female (40) | Respiratory distress, acute hemolytic anemia, Shock requiring pressure support, Myositis, Cardiogenic shock, Pancreatitis/rash | 1, 5, 7 days     | N/A                                    |
| Patrice Chevallier.        | France           | Prospective study  | PB             | 112    | 57  | Male (50.7) Female (62.2) | N/A | 7 days       | Pain, redness, Swelling Fever, Chills, Fatigue, Myalgia, Headache, Nausea |
| Laurence Chu.             | USA              | RCT Second phase   | M              | 600    | 18-87 | Male (35) Female (65) | N/A | 7 days       | Pain, Erythema, swelling, Lymphadenopathy Headache, fatigue, myalgia, arthralgia, nausea/vomiting, chills |
| Coggins.                   | USA              | Cohort study       | PB             | 206    | 42.4 | Male (30.6) Female (69.4) | N/A | N/A         | Soreness, pain Fatigue, headache, myalgia, arthralgia, fever, chills, Lymphadenopathy |
Table 1: Severe adverse events, local and systemic side effects of mRNA COVID-19 vaccination

| First Author Country | Study type | Manufacturer* | Sample | Age | Gender (%) | Severe adverse event | Time to appearance | Side effects (%) |
|----------------------|------------|----------------|--------|-----|------------|---------------------|------------------|-----------------|
| Efrati. (97) Israel  | Cohort study | PB             | 333    | 46  | Male (51) Female (49) | N/A                | At least 7 days | Pain, redness, and swelling |
|                      |            |                |        |     |            |                     |                  | Fever, chills, Headache, Nausea, Vomiting, Diarrhea, Muscle aches, joint aches, Allergic reaction |
| Nagla A El-Shitany. (98) Saudi Arabia Retrospective | Cross-sectional | PB | 455 | N/A | Male (35.8) Female (64.2) | N/A | N/A | Arm pain, injection site pain, swelling, and redness | Whole-body pain, muscle ache, joint ache, hypersensitivity, burning sensation in the eye |
| Robert W. French. (99) Multi-national African American, American Indian or Alaska, Asian, Latin | RCT Third phase | PB | 2260 | 12-25 | Male (51) Female (49) | N/A | 7 days | Pain at the injection site, Swelling, Redness | Fatigue, Headache, Chills, Muscle pain, joint pain, fever, diarrhea, vomiting |
| Miguel García-Grimshaw. (40) Mexico | Prospective observational cohort | PB | 704,003 | 36 | Male (74.2) Female (26.8) | 0.005 with no observed deaths | 3 to 5 hours | Injection site pain | Headache, Fatigue, Muscle pain, joint pain, chills, Nausea, Fever, Tachycardia, Rhinorrhea, Diarrhea, vomiting, irritability |
| Yarden Golan. (100) USA African American, white, Asian | Cohort study | PB, M | 50 | 35 | Female (100) | none | 80 days | Pain, redness, swelling, itching, rash around the injection site | Fever, Chills, Headache, Joint pain, Muscle/body aches, fatigue, Nausea, Diarrhea |

Time to appearance: Time from injection to the appearance of adverse events; *PB, Pfizer BioNTech; M, Moderna.

RCT: randomized controlled trial